JMP reiterates Human Genome at market outperform

Human Genome Sciences, Inc. was reiterated at market outperform with a $15 price target by JMP Securities analyst Charles C. Duncan. The company announced results from an interim analysis of Albuferon in interferon (IFN)-naïve and IFN-experienced hepatitis C patients that showed equivalent efficacy given once every two weeks compared to a weekly dose of standard of care, Pegasys (Roche). The high dose once-every-four-week regimen was shown to be less effective at week 12, but was given a more favorable safety profile. The analyst looks for more data from the phase 2 program. Shares of the Rockville, Md., biopharmaceutical services company were down 5 cents, or 0.44%, at $11.25 on volume of 3,331,387 shares versus the three-month running average of 4,160,950 shares. (Nasdaq: HGSI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.